- NORTH CAROLINA SOCIETY OF GASTROENTEROLOGY
- 704.376.3688
- sbuchanan@meckmed.org
- All
- Alcoholic Hepatitis
- Ascites
- Barrett’s Esophagus
- Celiac Disease
- Crohn’s Disease
- Eosinophilic Esophagitis
- Eosinophilic Gastritis and/or Eosinophilic Duodenitis
- Gastroesophageal Reflux Disease
- Intraductal Papillary Mucinous Neoplasms
- Nonalcoholic Steatohepatitis
- Primary Biliary Cholangitis
- Primary Sclerosing Cholangitis
- Ulcerative Colitis
September 10, 2021
A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects with Nonalcoholic Steatohepatitis and Fibrosis Study […]
May 31, 2021
Study title Phase 1, Open Label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in […]
May 31, 2021
Study title ECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative […]
May 31, 2021
Study title A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis (QUASAR) Disease or condition Ulcerative colitis Study type Interventional (Clinical Trial) […]
May 31, 2021
Study title A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and […]
May 31, 2021
Study title Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (SHIP) Disease or condition Primary sclerosing cholangitis Study type Interventional (Clinical Trial) Intervention/treatment Sulfasalazine or placebo Phase 2 Study […]
May 31, 2021
Note: this study is at multiple sites in North Carolina Study title Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis (PRIMIS) […]
May 31, 2021
Study title A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to evaluate efficacy and safety of Elafibranor 80 mg in Patients with Primary Biliary […]
May 31, 2021
Study title ARMOR: Phase 3/4 Double-Blind, Placebo-Controlled Clinical Study to Evaluate Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH) Disease or condition NAFLD/NASH with Fibrosis Study type […]